Brief: Theseus Pharmaceuticals Nominates The-349, A Fourth-Generation EGFR Inhibitor Development Candidate In Non-Small Cell Lung Cancer
03/10/2022 12:19
Oct 3 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS NOMINATES THE-349, A
FOURTH-GENERATION
EGFR INHIBITOR DEVELOPMENT CANDIDATE IN NON-SMALL CELL LUNG
CANCER
* THESEUS PHARMACEUTICALS INC - IND SUBMISSION ANTICIPATED
IN H2
2023
Source text for Eikon: ID:nPn118kLQa
Further company coverage: THRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7